CIP
VKTX icon

Cornerstone Investment Partners’s Viking Therapeutics VKTX Stock Holding History

Cornerstone Investment Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-17,825
Closed -$100K – 298
2020
Q4 		$100K Hold
17,825
– – 0.01% 204
2020
Q3 		$104K Hold
17,825
– – 0.01% 159
2020
Q2 		$129K Buy
+17,825
New +$118K 0.01% 155

Other funds holding VKTX

ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Cornerstone Investment Partners's VKTX Position: Q1 2021 in Review

Cornerstone Investment Partners sold out of Viking Therapeutics (VKTX) in Q1 2021, closing a stake of 17,825 shares — an estimated $100K sold.

Cornerstone Investment Partners first reported a position in VKTX in Q2 2020 and held it in 3 quarters. The position peaked at $129K in Q2 2020. 144 funds tracked by Wall St. Rank hold VKTX as of Q1 2021.

  • Cornerstone Investment Partners reported no remaining Viking Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Cornerstone Investment Partners sold 17,825 Viking Therapeutics shares in Q1 2021, an estimated $100K.
  • Cornerstone Investment Partners first reported a position in Viking Therapeutics in Q2 2020 and held it in 3 quarters.
  • Cornerstone Investment Partners's Viking Therapeutics position peaked at $129K in Q2 2020.
  • 144 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2021.

Based on Cornerstone Investment Partners's 13F filing for Q1 2021, filed 26 Apr 2021.